NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Seagen Inc.
Bristol-Myers Squibb
University of Oxford
Ludwig Institute for Cancer Research
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute